Rifaximin

Rifaximin is an antibiotic derived from rifamycin SV (Cay-21441) that inhibits the growth of a variety of Gram-positive and Gram-negative bacteria in vitro, including Staphylococcus, Streptococcus, Enterococcus, H. influenzae, and N. gonorrhoeae (MIC50s = =0.015, 50 = ~20 µM) that reduces colonic damage, rectal bleeding, and diarrhea in PXR-humanized, but not wild-type or Pxr-null, mice with inflammatory bowel disease (IBD) induced by dextran sulfate sodium (DSS, Cay-23250). Rifaximin exhibits minimal intestinal absorption after oral administration and is, therefore, effective in eliminating bacteria in the gastrointestinal system. Formulations containing rifaximin have been used in the treatment travelers' diarrhea caused by noninvasive E. coli, irritable bowel syndrome with diarrhea (IBS-D), and to reduce the risk of recurrence of overt hepatic encephalopathy.Formal Name: (2S,18E,28E)-25S-(acetyloxy)-5,6,21S,23R-tetrahydroxy-27S-methoxy-2,4,11,16Z,20S,22R,24R,26R-octamethyl-2,7-(epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione. CAS Number: 80621-81-4. Synonyms: L 105SV, Rifamycin L 105. Molecular Formula: C43H51N3O11. Formula Weight: 785.9. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/ml, DMSO: 10 mg/ml, Ethanol: 30 mg/ml, Ethanol:PBS(pH 7.2) (1:1): 0.5 mg/ml. lambdamax: 219, 238, 294, 373, 458 nm. SMILES: OC1=C(NC(/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)/C=C/O[C@@](C2=O)(C)O3)=O)C4=C(N=C5N4C=CC(C)=C5)C6=C2C3=C(C)C(O)=C61. InChi Code: InChI=1S/C43H51N3O11/c1-19-14-16-46-28(18-19)44-32-29-30-37(50)25(7)40-31(29)41(52)43(9,57-40)55-17-15-27(54-10)22(4)39(56-26(8)47)24(6)36(49)23(5)35(48)20(2)12-11-13-21(3)42(53)45-33(34(32)46)38(30)51/h11-18,20,22-24,27,35-36,39,48-51H,1-10H3,(H,45,. InChi Key: NZCRJKRKKOLAOJ-XRCRFVBUSA-N.